Jonah Feldman is an editor for Targeted Oncology covering multiple myeloma, melanoma, and sarcomas. Contact him at jfeldman@targeteonc.com.
When comparing patients with metastatic castration-resistant prostate cancer who have homologous recombination repair deficiency mutations, those with BRCA mutations have worse outcomes compared to patients without the BRCA mutation in their disease.
A comprehensive analysis of the phase 1 LEGEND-2 study shows a correlation between cytokine release syndrome and coagulation disorders inpatient with multiple myeloma treated with CAR T cells.
An analysis of Medicare patients with follicular lymphoma revealed which characteristics correlated with overall survival.
Findings from a survey found that many physicians used new strategies to manage their patients during the COVID-19 pandemic, some of which, such as the use of telehealth, are expected to continue into the future.
In an interview with Targeted Oncology for World Ovarian Cancer Day, Natalie Godbee, DO, discussed the current state of treatment for advanced ovarian cancer and how oncologists can get the best outcomes for their patients.
It was announced that the phase 3 EMBARK study met its primary end point in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.
In an interview with Targeted Oncology for Melanoma Monday, Meredith McKean, MD, MPH, discussed recent and upcoming advances in melanoma treatment.
A trial of TOS-358, a first-in-class covalent PI3Kα inhibitor, for various solid tumors dosed its first patient.
Studies have increasingly supported the use of total neoadjuvant therapy, moving chemotherapy use ahead of surgical resection of rectal tumors.
In an interview with Targeted Oncology for Esophageal Cancer Awareness Month, Arturo Loaiza-Bonilla, MD, MSEd, discussed the pressing need to keep up with the developments in targeted therapies for esophageal and GEJ cancers.
The addition of eftilagimod alpha to pembrolizumab in patients with PD-1 resistant non–small cell lung cancer led to tumor shrinkage.
The rise of earlier-onset disease and the introduction of noninvasive testing has changed the landscape of colorectal cancers for oncologists.
The FDA released a draft guidance for drug sponsors of clinical trials in oncology, outlining its move toward requiring randomized controlled trials to grant accelerated approvals for most oncology therapeutics.
A patient who received AB8939, a microtubule inhibitor, in a phase 1 study, had a significant reduction in bone marrow blasts, showing its potential to treat drug-resistant acute myeloid leukemia.
A study of isatuximab and cemiplimab in 3 lymphoma subtypes will not continue, for reasons unrelated to safety.
Investigators from the China ARCHES trial of enzalutamide plus androgen deprivation therapy announced that it had met its primary end point in Chinese patients with metastatic hormone-sensitive prostate cancer.
Results were published from a phase 1b trial of patients with higher-risk myelodysplastic syndromes, showing strong efficacy and safety outcomes.
Following positive phase 1 results in patients with previously treated advanced urothelial carcinoma, the FDA granted Fast Track Designation for the novel AHR inhibitor IK-175.
The LIMBER-304 trial of parsaclisib plus ruxolitinib in patients with myelofibrosis who did not sufficiently respond to ruxolitinib was discontinued after preplanned interim analysis.
In an interview with Targeted Oncology, Shaji K. Kumar, MD, discussed the presentations from ASH 2022 that stood out as most important to the multiple myeloma landscape.
Patrick Wagner, MD, director of complex general surgical oncology at AHN Cancer Institute, discussed the current state of important developments in treatment of gallbladder cancer.
According to findings presented at the 2023 Transplantation & Cellular Therapy Meetings, experts did not identify clear correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib in patients with graft-vs-host-disease.
Risk of relapse was significantly greater for those with acute lymphoblastic leukemia who had low minimal residual disease of less than 10-4 vs those with undetectable MRD, according to results of a retrospective study.
Early results announced from the VITALIZE study show efficacy and safety of maveropepimut-S plus pembrolizumab and low-dose, intermittent cyclophosphamide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Patients treated with brexucabtagene autoleucel as standard of care in US Lymphoma CAR T Consortium centers responded to treatment consistently with the ZUMA-2 trial, showing real-world efficacy and safety as well as additional data on outcomes for patients with high-risk features and different bridging therapies.
In an interview with Targeted Oncology™, Nathan Bahary, MD, PhD, discussed adapting to new therapy options and what the future holds for improving care for patients with cholangiocarcinoma.
Results of a study of dabrefenib, trametinib, and spartalizumab showed efficacy for the combination of a BRAF inhibitor, a MEK inhibitor, and an anti–PD-1 agent in patients with BRAF V600-mutated colorectal cancer.
The phase 1 POLARIS trial showed a 100% overall response rate for OriCAR-017, a novel CAR T-cell therapy with a new target in relapsed/refractory multiple myeloma.
Elacestrant has recieved FDA approval for the treatment of patients with estrogen receptor-positive/HER2-negative advanced or metastatic breast cancer.
Results from the CRC-PREVENT trial of a noninvasive diagnostic screening test have led to the submission of a premarket approval application to the FDA for patients with colorectal cancer and advanced adenomas.